A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

Trial Profile

A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs GS 030 (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; First in man
  • Acronyms PIONEER
  • Sponsors GenSight Biologics
  • Most Recent Events

    • 25 Oct 2017 Status changed from planning to not yet recruiting.
    • 31 Jan 2017 According to GenSight Biologics media release, the company announced that the the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to GS030 for the treatment of retinitis pigmentosa.
    • 21 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top